<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35282924</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>41 Suppl 1</Volume><Issue>Suppl 1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal.</ArticleTitle><Pagination><StartPage>A70</StartPage><EndPage>A78</EndPage><MedlinePgn>A70-A78</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2022.02.058</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(22)00204-3</ELocationID><Abstract><AbstractText>Following the global declaration of indigenous wild poliovirus type 2 eradication in 2015, the world switched to oral polio vaccine (OPV) that removed the type 2 component. This 'switch' included the widespread introduction of inactivated poliovirus vaccine and the creation of a stockpile of monovalent type 2 OPV (mOPV2) to respond to potential polio virus Type 2 (PV2) outbreaks and events. With subsequent detection of outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2), it was necessary to use this stockpile for outbreak response. Not only were more outbreaks detected than anticipated in the first few years after the switch, but the number of supplemental immunization activities (SIAs) used to stop transmission was often high, and in many cases did not stop wider transmission. Use of mOPV type 2 led in some locations to the emergence of new outbreaks that required further use of the vaccine from the stockpile. In the following years, stockpile management became a critical element of the cVDPV2 outbreak response strategy and continued to evolve to include trivalent OPV and genetically stabilized 'novel OPV type 2' vaccines in the stockpile. An overview of this process and its evolution is presented to highlight several of these management challenges. The unpredictable vaccine demand, fixed production and procurement timelines, resource requirements, and multiple vaccine types contributes to the complexity of assuring appropriate vaccine availability for this critical programmatic need to stop outbreaks.</AbstractText><CopyrightInformation>Copyright © 2022. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harutyunyan</LastName><ForeName>Vachagan</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>World Health Organization, Geneva, Switzerland. Electronic address: harutyunyanv@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quddus</LastName><ForeName>Arshad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallansch</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zipursky</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woods</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>World Health Organization, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ottosen</LastName><ForeName>Ann</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UNICEF Supply Division, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vertefeuille</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>UNICEF Supply Division, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Outbreak Response</Keyword><Keyword MajorTopicYN="N">Poliovirus Vaccine</Keyword><Keyword MajorTopicYN="N">Vaccine Stockpile</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>14</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35282924</ArticleId><ArticleId IdType="pmc">PMC10427718</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.058</ArticleId><ArticleId IdType="pii">S0264-410X(22)00204-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. World Health Assembly. Global eradication of poliomyelitis by the year 2000 (resolution 41.28). 1988 [cited 2021 June 29]; Available from: https://polioeradication.org/wp-content/uploads/2016/07/19880513_resolution-2.pdf.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Our progress against polio. 2021 [cited 2021 June 29]; Available from: https://www.cdc.gov/polio/progress/index.htm.</Citation></Reference><Reference><Citation>World Health Organization. Global eradication of wild poliovirus type 2 declared. 2015 [cited 2021 June 21]; Available from: https://polioeradication.org/news-post/global-eradication-of-wild-poliovirus-type-2-declared/.</Citation></Reference><Reference><Citation>World Health Organization. Oral Polio Vaccine Switch On Track for April 2016. 2015 [cited 2021 June 29]; Available from: https://polioeradication.org/news-post/oral-polio-vaccine-switch-on-track-for-april-2016/.</Citation></Reference><Reference><Citation>World Health Organization. World Health Assembly, Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1). 2008 [cited 2021 June 29]; Available from: https://polioeradication.org/wp-content/uploads/2016/07/WHA61_Resolution_English.pdf.</Citation></Reference><Reference><Citation>Nguyen T., Richardson S., Garcia E.V., Harutyunyan V., Costa A., Gamhewage G., et al. Access to life-saving vaccines during outbreaks: a spotlight on governance. Wkly Epidemiol Rec. 2018;93(20):284–290.</Citation></Reference><Reference><Citation>World Health Organization. OPV Cessation: Plan for tOPV Campaigns Immediately Prior to tOPV to bOPV Switch. 2014 [cited 2021 June 29]; Available from: https://www.who.int/immunization/sage/meetings/2014/october/5_Plan_for_tOPV_Campaigns_v21.pdf.</Citation></Reference><Reference><Citation>Duintjer Tebbens R.J., Thompson K.M. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Rev Vaccines. 2018;17(8):739–751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6168953</ArticleId><ArticleId IdType="pubmed">30056767</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Polio Post-Certification Strategy: A risk mitigation strategy for a polio-free world. 2018 [cited 2021 June 29]; Available from: https://polioeradication.org/wp-content/uploads/2018/04/polio-post-certification-strategy-20180424-2.pdf.</Citation></Reference><Reference><Citation>World Health Organization. Poliomyelitis: intensification of the global eradication initiative. Report by the Secretariat (A67/38). 2014 [cited 2021 June 29]; Available from: https://polioeradication.org/wp-content/uploads/2016/07/A67_38-en.pdf.</Citation></Reference><Reference><Citation>World Health Organization. Poliomyelitis. Resolution WHA68.3. 2015 [cited 2021 June 29]; Available from: https://polioeradication.org/wp-content/uploads/2016/07/A68_R3-en.pdf.</Citation></Reference><Reference><Citation>World Health Organization. WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use: GAPIII. 2015 [cited 2021 June 29]; Available from: https://polioeradication.org/wp-content/uploads/2016/12/GAPIII_2014.pdf.</Citation></Reference><Reference><Citation>World Health Organization. Guidance to minimize risks for facilities collecting, handling or storing materials potentially infectious for polioviruses. 2018 [cited 2021 June 29]; Available from: https://polioeradication.org/wp-content/uploads/2018/06/polio-containment-guidance-for-non-poliovirus-facilities-20180614-en.pdf.</Citation></Reference><Reference><Citation>World Health Organization. Operational Framework for Monovalent Oral Poliovirus Type 2 (mOPV2) deployment and replenishment (during the endgame period). 2014 [cited 2021 June 29]; Available from: https://www.who.int/immunization/sage/meetings/2014/october/4_Polio_mOPV2_stockpile_v4_09_10_2014.pdf.</Citation></Reference><Reference><Citation>World Health Organization. GPEI Strategy for the Response to cVDPV2: 2020-2021. 2020 [cited 2021 June 29]; Available from: https://polioeradication.org/wp-content/uploads/2021/03/GPEI-cVDPV2-nOPV2-Factsheet-20210312-EN.pdf.</Citation></Reference><Reference><Citation>World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, 31 March–1 April 2020: conclusions and recommendations. Wkly Epidemiol Rec, 2020; 95(22): 241–56.</Citation></Reference><Reference><Citation>Duintjer Tebbens R.J., et al. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect Dis. 2016;16:137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806487</ArticleId><ArticleId IdType="pubmed">27009272</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394(10193):148–158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I., Leroux-Roels I., Bandyopadhyay A.S., Gast C., Withanage K., Steenackers K., et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2021;397(10268):39–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sáez-Llorens X., Bandyopadhyay A.S., Gast C., Leon T.D., DeAntonio R., Jimeno J., et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021;397(10268):27–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska D.A., Pallansch M.A., Wilkinson A., Bandyopadhyay A.S., Konopka‐Anstadt J.L., Burns C.C., et al. Updated characterization of outbreak response strategies for 2019–2029: impacts of using a novel type 2 oral poliovirus vaccine strain. Risk Anal. 2021;41(2):329–348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887065</ArticleId><ArticleId IdType="pubmed">33174263</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Recommendation for an emergency use listing (EUL) of novel oral polio vaccine type 2 (nOPV2) submitted by PT Biofarma (Persero). 2020 [cited 2021 June 29]; Available from: https://extranet.who.int/pqweb/sites/default/files/documents/nOPV2_EUL_recommendation.pdf.</Citation></Reference><Reference><Citation>Thompson K.M., Pallansch M.A., Tebbens R.J.D., Wassilak S.G., Cochi S.L. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal. 2013;33(4):647–663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896539</ArticleId><ArticleId IdType="pubmed">22985171</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>